<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18486">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02122510</url>
  </required_header>
  <id_info>
    <org_study_id>1004/02/12</org_study_id>
    <nct_id>NCT02122510</nct_id>
  </id_info>
  <brief_title>Transverse Abdominal Block for Analgesia in Casarean Section</brief_title>
  <official_title>The Value of Preemptive Dexmedetomidine Transversus Abdominis Plane (TAP) Block in Patients Undergoing Elective Cesarean Section Under General Anesthesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will compare the analgesic effect of bupivacaine and
      bupivacaine-dexmetomedine after elective cesarean delivery by performing an bilateral TAP
      block, on the patients for whom the operation will be performed under general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study 60 ASA [American Society of Anesthesiologist] physical status I
      and ІІ patients undergoing elective cesarean delivery at tanta University Hospital, in a
      prospective, randomized, comparative, clinical trial.

      Patients will be randomly allocated to two equal groups (n = 30) using closed envelopes
      labeled 1,and 2 reflecting group 1and 2 respectively.

      The drugs are prepared by the anesthesiologist who is not involved in the study or data
      collection.

      Group I: (n=30) will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5
      % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.

      Group II: (n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine
      0.5 % mixed with 10 ml saline in 20 ml syringe labeled G2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>hemodynamic changes</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood pressure and heart rate measured every 15 minutes during the intraopertive peroid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirements</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>VAS will be measured during 24 hours after surgery every 4 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Analgesia Disorder</condition>
  <arm_group>
    <arm_group_label>dexmetomedine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine  group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine  group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacine group</intervention_name>
    <description>Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe</description>
    <arm_group_label>Bupivacaine  group</arm_group_label>
    <other_name>Bucaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe</description>
    <arm_group_label>dexmetomedine group</arm_group_label>
    <other_name>precdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. We will study 60 ASA [American Society of Anesthesiologist] physical status I and ІІ
             patients undergoing elective cesarean delivery

          2. Age between 21-40 years old.

        Exclusion Criteria:

          1. Refusal of participation in the study

          2. Patients who have infection or tumor at the site of puncture for local anesthetic
             injection.

          3. Patients who have coagulopathy, platelet abnormalities, and concurrent treatment with
             anticoagulant drugs.

          4. Patients known to have allergy or sensitivity to dexmetomedine, and/or bupivacaine

          5. Severe hepatic and/or renal insufficiency

          6. Morbid obesity (body mass index (BMI) &gt;35)

          7. Psychological disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman A Yousef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman A Yousef, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman A Yousef, MD</last_name>
    <phone>00201003497767</phone>
    <email>ayman.yousef@rocketmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <state>Algharbiya</state>
        <zip>355217</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman A Yousef, MD</last_name>
      <phone>00201003497767</phone>
      <email>ayman.yousef@rocketmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ayman A Yousef, MD</last_name>
      <phone>002001003497767</phone>
      <email>ayman.yousef@rocketmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amira A Mahfouz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman Abd Al-maksoud Yousef</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Analgesia, casarean section, TAP block</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
